Advertisement

Topics

Aerie Pharmaceuticals Announces Resubmission of NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02%

06:30 EST 1 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the e...

Other Sources for this Article

Aerie Pharmaceuticals
Richard Rubino, 908-947-3540
rrubino@aeriepharma.com
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Investors
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
Media
Justin Jackson, 212-213-0006
jjackson@burnsmc.com

NEXT ARTICLE

More From BioPortfolio on "Aerie Pharmaceuticals Announces Resubmission of NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02%"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...